Reader response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study

This phase 2b double-blind study by Bar-Or et al.1 provided evidence for a reduction in inflammatory MRI lesions in relapsing forms of multiple sclerosis (MS) following treatment with subcutaneous ofatumumab. However, the 90% reduction in gadolinium-enhancing lesions seen from week 4 onward could be considered inflated in the absence of an active comparator. In contrast, the phase 2 trial of alemtuzumab provided comparison to interferon.2 The question remains “What will be the long-term outcome for the placebo group in the MIRROR study?” although they received a single 3-mg dose of ofatumumab at week 12.1